HRTX - Heron Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
37.75
-0.35 (-0.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close38.10
Open38.15
Bid0.00 x 40700
Ask0.00 x 900
Day's Range37.35 - 38.30
52 Week Range14.40 - 42.90
Volume647,397
Avg. Volume1,283,957
Market Cap2.907B
Beta1.46
PE Ratio (TTM)N/A
EPS (TTM)-3.46
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.00
Trade prices are not sourced from all markets
  • ACCESSWIRE13 days ago

    Free Pre-Market Technical Recap on Sanofi and Three Additional Drug Makers Stocks

    On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drug Manufacturers - Major equities this morning: Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Sanofi (NYSE: SNY).

  • ACCESSWIRE21 days ago

    Today's Research Reports on Trending Tickers: Heron Therapeutics and Array BioPharma

    NEW YORK, NY / ACCESSWIRE / June 28, 2018 / U.S. equities fell sharply on Wednesday, weighed by losses from the consumer staples and technology sectors. The Dow Jones Industrial Average decreased 0.68 ...

  • Is There An Opportunity With Heron Therapeutics Inc’s (NASDAQ:HRTX) 33.58% Undervaluation?
    Simply Wall St.22 days ago

    Is There An Opportunity With Heron Therapeutics Inc’s (NASDAQ:HRTX) 33.58% Undervaluation?

    I am going to run you through how I calculated the intrinsic value of Heron Therapeutics Inc (NASDAQ:HRTX) by projecting its future cash flows and then discounting them to today’sRead More...

  • Business Wire23 days ago

    Heron Therapeutics Announces Pricing of Public Offering of Common Stock

    Heron Therapeutics, Inc. (“Heron”) (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of shares of its common stock. The offering is expected to close on or about June 28, 2018, subject to customary closing conditions.

  • Business Wire23 days ago

    Heron Therapeutics Announces Public Offering of Common Stock

    Heron Therapeutics, Inc. (“Heron”) (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of shares of its common stock. All of the shares of common stock in the offering are to be sold by Heron.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool26 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these sizzling biotech stocks stay hot?

  • Benzinga27 days ago

    Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 21) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) FibroGen Inc (NASDAQ: ...

  • ACCESSWIRE27 days ago

    Today’s Research Reports on Stocks to Watch: Heron Therapeutics and Stellar Biotechnologies

    NEW YORK, NY / ACCESSWIRE / June 22, 2018 / Biotech stocks Heron Therapeutics and Stellar Biotechnologies were gaining like wildfire in Thursday’s trading session with both companies releasing positive ...

  • MarketWatch27 days ago

    Heron Therapeutics stock rockets 30% on high hopes for post-surgery pain treatment

    Heron Therapeutics Inc. shares surged 30% Thursday, after the company announced positive developments for its treatment for postoperative pain that aims to reduce patient dependence on opioids. It then said that its HTX-011, which was the focus of the two studies, has won breakthrough therapy designation from the U.S. Food and Drug Administration. HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam and is intended for the management of postoperative pain.

  • Why Stitch Fix, Barnes & Noble Education, and Heron Therapeutics Jumped Today
    Motley Fool27 days ago

    Why Stitch Fix, Barnes & Noble Education, and Heron Therapeutics Jumped Today

    Find out which of these companies reported great financial results.

  • Why Heron Therapeutics Rose 33% in Pre-Market Trading Today
    Market Realist27 days ago

    Why Heron Therapeutics Rose 33% in Pre-Market Trading Today

    Why Heron Therapeutics Rose 33% in Pre-Market Trading TodayHeron Therapeutics stock surges in pre-market trading

  • Why Heron Therapeutics Stock Is Blasting Higher Today
    Motley Fool27 days ago

    Why Heron Therapeutics Stock Is Blasting Higher Today

    The FDA granted Heron's experimental pain medicine Breakthrough Therapy designation today.

  • MarketWatch28 days ago

    Drugs from Heron Therapeutics and two other biotech companies can boost your investment returns by reducing opioid abuse

    Heron Therapeutics, Cara Therapeutics and Alkermes are discovering novel replacements for dangerous opioidsAbout 2.1 million people in the U.S. suffer from opioid abuse. While investors are focused on trade wars as a potential threat to their wealth, drug abuse may be the bigger risk. Fortunately, three biotech companies are coming to the rescue, which makes them good investments.

  • MarketWatch28 days ago

    Heron Therapeutics shares surge 33% after positive FDA response to pain treatment

    Heron Therapeutics Inc. shares (hrtx) surged 33.6% in premarket trade Thursday, after the company announced positive developments for its treatments for postoperative pain. The company said it has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for HTX-011, an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain. Breakthrough Therapy designation is aimed at speeding up the development and review of drugs that treat serious conditions and that show signs of offering significant improvement over existing therapies.

  • Business Wire28 days ago

    HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA

    Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that HTX-011 for postoperative pain management has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). HTX-011 is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain. Breakthrough Therapy designation is designed to expedite the development and review of drugs that are intended to treat serious conditions and for which preliminary clinical evidence indicates substantial improvement over available therapies on clinically significant endpoint(s).

  • Business Wire28 days ago

    Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation

    Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced positive topline results from two completed Phase 2b studies of HTX-011: Study 209 (local administration in total knee arthroplasty) and Study 211 (instillation or pectoral pocket nerve block in breast augmentation). Study 209 was a randomized, placebo- and active-controlled, double-blind, Phase 2b clinical study in patients undergoing primary unilateral total knee arthroplasty to evaluate the analgesic efficacy, safety and pharmacokinetics of HTX-011 locally administered into the surgical site.

  • ACCESSWIRE2 months ago

    Breakfast Technical Briefing on Johnson & Johnson and Three Other Additional Healthcare Stocks

    Research reports have been issued by WallStEquities.com on Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Perrigo Co. PLC (NYSE: PRGO).

  • Business Wire2 months ago

    Heron Therapeutics to Present at the Jefferies 2018 Healthcare Conference

    Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018, at 2:00 p.m. EDT at the Grand Hyatt New York Hotel. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs.

  • 3 Stocks the World's Best Investors Are Buying Right Now
    Motley Fool2 months ago

    3 Stocks the World's Best Investors Are Buying Right Now

    Two stocks the world's best-known investor recently added to, and a little-known biotech getting the backing of a little-known (but very successful) pair of biopharma investors.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advaxis, ...

  • Associated Press2 months ago

    Heron Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 81 cents. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...

  • Business Wire2 months ago

    Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress

    Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today reported financial results for the three months ended March 31, 2018 and highlighted recent corporate progress.

  • Business Wire2 months ago

    Heron Therapeutics to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference

    Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Bank of America Merrill Lynch 2018 Healthcare Conference on Wednesday, May 16, 2018, at 1:00 p.m. PDT at the Encore Hotel in Las Vegas, NV. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs.

  • MarketWatch3 months ago

    Harry Boxer’s four biotech stocks to watch today

    Biotechnology stocks dominate our list of top charts to watch, with a uranium producer also advancing to the list. CASI Pharmaceuticals Inc.(CASI) rose 48 cents, or 7.2%, to $7.14 on 773,700 shares traded Tuesday. The move came on no news from the company, although the stock soared in early April on news that China’s Food and Drug Administration (CFDA) would convene a panel to discuss its cancer therapy, Evomela.

  • Don't Waste Your Money On Penny Stocks -- These 3 Stocks Are Better Buys
    Motley Fool3 months ago

    Don't Waste Your Money On Penny Stocks -- These 3 Stocks Are Better Buys

    Penny stocks are a great way to get scammed. Don't fall for the allure of riches that never materialize; here are three legitimate businesses that are better choices.